Myeloid Leukemia Associated With Down Syndrome

2

Review clinical trials related to Myeloid Leukemia Associated With Down Syndrome. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Participants needed: 960
Trial details
Phase: Phase 1, Phase 2Age: Up to 22Biological sex: AllType: InterventionalSponsor: PedAL BCU, LLCUpdated: Jun 18, 2026Locations: 183
Eligibility criteria

Patients must be less than 22 years of age at the time of study enrollment [+14]

Status: Recruiting

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.

Participants needed: 330
Trial details
Age: 6-39Biological sex: AllType: ObservationalSponsor: Children's Oncology GroupUpdated: May 5, 2026Locations: 70
Eligibility criteria

Patients age >= 6 and < 40 years at the time of enrollment [+12]

Patients with history of hematopoietic stem cell transplant (HSCT) are excluded [+4]